Alixorexton, a Novel Oral Orexin 2 Receptor Agonist, Shows Promising Safety and Efficacy in Narcolepsy Type 1: Insights from the Vibrance-1 Phase 2 Trial

Highlight

• Alixorexton, a selective oral orexin 2 receptor agonist, significantly improves wakefulness in patients with narcolepsy type 1 compared to placebo, as evidenced by increased mean sleep latency on the Maintenance of Wakefulness Test.
• Clinically meaningful reduction in excessive daytime sleepiness and cataplexy symptoms was observed after six weeks of daily dosing across multiple doses (4 mg, 6 mg, 8 mg).
• The safety profile of alixorexton was generally acceptable; adverse events aligned with known on-target OX2R agonist effects and were manageable.
• Vibrance-1 trial results strongly support advancing alixorexton into phase 3 studies, offering a promising new therapeutic option for narcolepsy type 1 patients.